BioNTech(BNTX.US)和再生元製藥擬擴大用於治療晚期非小細胞肺癌戰略合作
格隆匯3月8日丨BioNTech(BNTX.US)今天宣佈擴大其與再生元製藥(REGN.US)戰略合作,以推進該公司的FixVac候選藥物BNT116與PD-1抑制劑Libtayo®(Cymplimab)聯合用於治療晚期非小細胞肺癌。根據協議條款,兩家公司計劃聯合進行臨牀試驗,以評估它們在不同晚期非小細胞肺癌患者羣體中的組合。肺癌是世界範圍內最常見的惡性腫瘤類型之一,也是癌症死亡的主要原因。非小細胞肺癌是最常見的肺癌類型,約佔所有肺癌的85%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.